Mohamad-Gabriel Alameh

2 months ago | nature.com | Kelsey Swingle |Alex Hamilton |Ajay S. Thatte |Amanda Murray |Emily Han |Xuexiang Han | +2 more

Correction to: Nature https://doi.org/10.1038/s41586-024-08291-2 Published online 11 December 2024In the version of the article initially published, in Fig. 2b, the x-axis label “µg β2-GPI per µg lipid” has now been amended to “µg ApoE per µg lipid”. In Fig. 2d, the x-axis label “µg ApoE per µg lipid” has now been amended to “µg β2-GPI per µg lipid”. In the key for Figs. 3e–j, “LNP + LNP 55” was incorrect and has now been amended to “LPS + LNP 55”.

Dec 11, 2024 | nature.com | Kelsey Swingle |Alex Hamilton |Ajay S. Thatte |Amanda Murray |Emily Han |Xuexiang Han | +2 more

AbstractPre-eclampsia is a placental disorder that affects 3–5% of all pregnancies and is a leading cause of maternal and fetal morbidity worldwide1,2. With no drug available to slow disease progression, engineering ionizable lipid nanoparticles (LNPs) for extrahepatic messenger RNA (mRNA) delivery to the placenta is an attractive therapeutic option for pre-eclampsia.

Nov 21, 2024 | nature.com | Xuexiang Han |Mohamad-Gabriel Alameh |Rakan El-Mayta |Kelsey Swingle |Junchao Xu |Ningqiang Gong | +5 more

AbstractIonizable lipids largely determine the biocompatibility of lipid nanoparticles (LNPs) and the efficacy for mRNA delivery. Rational design and combinatorial synthesis have led to the development of potent and biodegradable ionizable lipids, yet methodologies for the stepwise optimization of ionizable lipid structure are lacking.

Oct 3, 2024 | science.org | Adrian C. Hayday |Nicola Festuccia |Roman C. Sarott |Mohamad-Gabriel Alameh

Editor’s summaryA stay in a hospital might resolve one health challenge, but it may introduce another: an intractable infection with Clostridioides difficile. This bacteria can thrive and produce toxins if the normal gut bacteria are knocked out by antibiotics. Alameh et al. have been developing a multivalent mRNA–lipid nanoparticle vaccine to protect vulnerable individuals against toxigenic C. difficile.

Oct 1, 2024 | nature.com | Lulu Xue |Gan Zhao |Ningqiang Gong |Xuexiang Han |Zebin Xiao |Junchao Xu | +11 more

AbstractSystemic delivery of messenger RNA (mRNA) for tissue-specific targeting using lipid nanoparticles (LNPs) holds great therapeutic potential. Nevertheless, how the structural characteristics of ionizable lipids (lipidoids) impact their capability to target cells and organs remains unclear.